|
AU2007317242B2
(en)
|
2006-11-08 |
2013-08-01 |
Neurocrine Biosciences, Inc. |
Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
|
|
CA2736409C
(en)
|
2008-09-18 |
2017-07-11 |
Auspex Pharmaceutical, Inc. |
Benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
US20120003330A1
(en)
|
2010-06-01 |
2012-01-05 |
Auspex Pharmaceuticals, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
WO2012000308A1
(zh)
*
|
2010-06-29 |
2012-01-05 |
中国药科大学 |
丁苯那嗪的拆分方法
|
|
US8351329B2
(en)
*
|
2010-09-14 |
2013-01-08 |
Cisco Technology, Inc. |
Universal load-balancing tunnel encapsulation
|
|
CN102285984B
(zh)
*
|
2010-11-25 |
2012-10-10 |
江苏威凯尔医药科技有限公司 |
(2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
|
|
WO2012081031A1
(en)
*
|
2010-12-15 |
2012-06-21 |
Enaltec Labs Pvt. Ltd. |
Process for preparing tetrabenazine
|
|
US9550780B2
(en)
|
2012-09-18 |
2017-01-24 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
EP4345100A3
(en)
|
2012-09-18 |
2024-04-10 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
EA201500801A1
(ru)
*
|
2013-01-31 |
2016-01-29 |
Ауспекс Фармацетикалс, Инк. |
Бензохинолоновые ингибиторы vmat2
|
|
EP3049087A4
(en)
*
|
2013-09-27 |
2017-05-24 |
Auspex Pharmaceuticals, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
NZ720301A
(en)
*
|
2013-12-03 |
2022-01-28 |
Auspex Pharmaceuticals Inc |
Deuterated tetrabenazine compounds
|
|
EA201691512A1
(ru)
|
2014-01-27 |
2017-01-30 |
Оспекс Фармасьютикалз, Инк. |
Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2
|
|
WO2015120317A1
(en)
*
|
2014-02-07 |
2015-08-13 |
Neurocrine Biosciences, Inc. |
Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
|
|
CA2938244A1
(en)
|
2014-02-07 |
2015-08-13 |
Auspex Pharamaceuticals, Inc. |
Novel pharmaceutical formulations
|
|
DK3105218T3
(da)
|
2014-02-13 |
2019-11-04 |
Incyte Corp |
Cyclopropylaminer som lsd1-inhibitorer
|
|
PT3936130T
(pt)
*
|
2014-05-06 |
2024-04-17 |
Neurocrine Biosciences Inc |
Regime de dosagem de valbenazina para o tratamento de distúrbios de movimento hipercinéticos
|
|
EP3253752B1
(en)
|
2015-02-06 |
2023-08-16 |
Neurocrine Biosciences, Inc. |
[9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
|
|
IL305352A
(en)
|
2015-03-06 |
2023-10-01 |
Auspex Pharmaceuticals Inc |
Methods for treating abnormal movement disorders
|
|
PE20180455A1
(es)
|
2015-04-03 |
2018-03-05 |
Incyte Corp |
Compuestos heterociclicos como inhibidores de lsd1
|
|
MX390795B
(es)
|
2015-06-23 |
2025-03-21 |
Neurocrine Biosciences Inc |
Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos.
|
|
UA126277C2
(uk)
|
2015-08-12 |
2022-09-14 |
Інсайт Корпорейшн |
Солі інгібітору lsd1
|
|
EP3359148A1
(en)
|
2015-10-09 |
2018-08-15 |
Teva Pharmaceuticals International GmbH |
Combination of deuterated levodopa with carbidopa and opicapone for the treatment of parkinson`s disease
|
|
WO2017075340A1
(en)
|
2015-10-30 |
2017-05-04 |
Neurocrine Biosciences, Inc. |
Valbenazine salts and polymorphs thereof
|
|
MA44127A
(fr)
*
|
2015-12-23 |
2018-10-31 |
Neurocrine Biosciences Inc |
Procédés de synthèse pour la préparation de di(4-méthylbenzènesulfonate) de 2-amino-3-méthylbutanoate de (s)-(2r,3r,11br)-3-isobutyl-9,10-diméthoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]isoquinoléin-2-yl
|
|
US10479787B2
(en)
|
2016-04-22 |
2019-11-19 |
Lupin Limited |
Process for preparation of tetrabenazine and deutetrabenazine
|
|
WO2018001335A1
(zh)
|
2016-06-29 |
2018-01-04 |
苏州科睿思制药有限公司 |
Nbi-98854的晶型及其制备方法和用途
|
|
RU2019110048A
(ru)
*
|
2016-10-06 |
2020-11-06 |
Ассиа Кемикал Индастрис Лтд. |
Твердые формы валбеназина
|
|
EP4400171A3
(en)
|
2016-12-02 |
2024-09-11 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating schizophrenia or schizoaffective disorder
|
|
WO2018130345A1
(en)
|
2017-01-10 |
2018-07-19 |
Sandoz Ag |
Crystalline valbenazine free base
|
|
KR20230038601A
(ko)
*
|
2017-01-27 |
2023-03-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 ｖｍａｔ2 억제제의 투여 방법
|
|
CA3054238A1
(en)
|
2017-02-27 |
2018-08-30 |
Sandoz Ag |
Crystalline forms of valbenazine salts
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
WO2018170214A1
(en)
|
2017-03-15 |
2018-09-20 |
Zhang Chengzi |
Analogs of deutetrabenazine, their preparation and use
|
|
GB201705303D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705306D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705302D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705304D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
AU2018241940B2
(en)
*
|
2017-04-01 |
2023-09-28 |
Adeptio Pharmaceuticals Limited |
Dihydrotetrabenazine for use in the treatment a movement disorder
|
|
JOP20190239A1
(ar)
*
|
2017-04-19 |
2019-10-09 |
Neurocrine Biosciences Inc |
مركبات مثبطة لـ vmat2 وتركيبات منها
|
|
US20200179352A1
(en)
|
2017-04-26 |
2020-06-11 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
CA3076000A1
(en)
|
2017-09-21 |
2019-03-28 |
Neurocrine Biosciences, Inc. |
High dosage valbenazine formulation and compositions, methods, and kits related thereto
|
|
MY198713A
(en)
|
2017-10-10 |
2023-09-19 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
SG11202004165UA
(en)
*
|
2017-11-08 |
2020-06-29 |
Yuhua Li |
Esters of dihydrotetrabenazine
|
|
EP3713938A1
(en)
|
2017-11-22 |
2020-09-30 |
Assia Chemical Industries Ltd |
Solid state form of valbenazine
|
|
CN110621674B
(zh)
|
2017-12-26 |
2022-03-29 |
苏州科睿思制药有限公司 |
一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途
|
|
CN110092785A
(zh)
*
|
2018-01-31 |
2019-08-06 |
广东东阳光药业有限公司 |
一种丁苯那嗪的动态拆分方法
|
|
GB201808464D0
(en)
|
2018-05-23 |
2018-07-11 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compounds for use in treating huntington's disease
|
|
EP3806856A1
(en)
*
|
2018-06-14 |
2021-04-21 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitor compounds, compositions, and methods relating thereto
|
|
EP3836926A4
(en)
|
2018-08-15 |
2022-05-04 |
Neurocrine Biosciences, Inc. |
METHOD OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
|
|
WO2020047198A1
(en)
|
2018-08-31 |
2020-03-05 |
Incyte Corporation |
Salts of an lsd1 inhibitor and processes for preparing the same
|
|
EP3860599B1
(en)
|
2018-10-04 |
2024-05-15 |
Adeptio Pharmaceuticals Limited |
(+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
|
|
CA3065236A1
(en)
|
2018-12-27 |
2020-06-27 |
Apotex Inc. |
Novel crystalline form of valbenazine dibesylate
|
|
WO2020213014A1
(en)
|
2019-04-19 |
2020-10-22 |
Mylan Laboratories Limited |
An improved process for the preparation of valbenazine and its salts
|
|
US10689380B1
(en)
|
2019-07-30 |
2020-06-23 |
Farmhispania S.A. |
Crystalline forms of valbenazine ditosylate
|
|
WO2021027792A1
(zh)
*
|
2019-08-12 |
2021-02-18 |
山东绿叶制药有限公司 |
Vmat2抑制剂及其制备方法和应用
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
CA3150961A1
(en)
|
2019-09-13 |
2021-03-18 |
John Tucker |
Processes for the synthesis of valbenazine
|
|
CN110698397A
(zh)
*
|
2019-10-28 |
2020-01-17 |
南京红杉生物科技有限公司 |
丁苯那嗪中间体及其合成方法、应用和合成用中间产物
|
|
CR20230448A
(es)
|
2021-03-22 |
2023-10-27 |
Neurocrine Biosciences Inc |
Inhibidores de vmat2 y métodos de uso
|
|
WO2022232060A1
(en)
|
2021-04-26 |
2022-11-03 |
Neurocrine Biosciences, Inc. |
Processes for the synthesis of valbenazine
|
|
BR112023026691A2
(pt)
|
2021-06-30 |
2024-03-05 |
Neurocrine Biosciences Inc |
Valbenazina para uso no tratamento complementar de esquizofrenia
|
|
AU2022302155A1
(en)
|
2021-06-30 |
2024-02-08 |
Neurocrine Biosciences, Inc. |
Valbenazine for use in the treatment of dyskinesia due to cerebral palsy
|
|
IL315181A
(en)
|
2022-03-07 |
2024-10-01 |
Neurocrine Biosciences Inc |
Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
|
|
CA3267926A1
(en)
|
2022-09-21 |
2024-03-28 |
Neurocrine Biosciences, Inc. |
HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLINE VMAT2 INHIBITORS AND METHODS OF USE
|
|
TW202521119A
(zh)
|
2023-08-17 |
2025-06-01 |
美商紐羅克里生物科學有限公司 |
用於投與特定vmat2抑制劑之方法
|
|
WO2025038959A1
(en)
|
2023-08-17 |
2025-02-20 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025096823A1
(en)
|
2023-11-01 |
2025-05-08 |
Neurocrine Biosciences, Inc. |
Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
|
|
WO2025188830A1
(en)
|
2024-03-06 |
2025-09-12 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025199234A1
(en)
|
2024-03-20 |
2025-09-25 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors and methods of use
|